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Abstract 
 
Flaxseed is classified as a functional food and is renowned for its exceptional 
nutrional value.  These foods have the ability to either promote overall well-being and/or 
reduce the risk of certain diseases.  Flaxseed, in the form of seed-derived oil, is the 
highest plant source of the omega-3 fatty acid, alpha linolenic acid.  This nutraceutical 
has been credited with providing protective benefits against breast, colon and prostate 
cancers.  Humans are unable to synthesize omega-3 fatty acids within the body and 
therefore must obtain sufficient amounts of this antioxidant through diet alone.   
Currently, the Western diet is grossly deficient in omega-3 fatty acids and this is 
in part due to the overwhelming presence of omega-6 fatty acids used in food processing 
and manufacturing techniques.  As one of the highest sources of omega-3 fatty acids, 
flaxseed is often taken as a supplement to help balance the ratio of omega-3 to omega-6 
fatty acids in Western cultures.  Although flaxseed has been beneficial in alleviating 
certain symptoms in patients suffering from cardiovascular disease, diabetes, and cancer, 
the underlying mechanisms remain unclear. Previous animal studies have shown that a 
diet supplemented with 10% flaxseed, significantly decreased tumour growth in rodent 
cancer models.  Our studies include the treatment of malignant cells with flaxseed oil in 
an in vitro model.  We have shown that flaxseed oil has the ability to reduce cell growth 
in B16-BL6 cells, an aggressive murine melanoma.   Furthermore, a total of seven 
different oils containing high concentrations of omega fatty acids, including flaxseed oil, 
olive, sunflower, canola, sesame, peanut and grapeseed, were characterized by HPLC and 
GC/MS analysis for fatty acid profiles, and these oils were also used to treat B16-BL6 
cells.  Although all seven oils contain various amounts of omega-3, -6 or -9 fatty acids, 
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only treatment with flaxseed oil decreased the growth of the aggressive murine melanoma 
cell line B16-BL6.  DNA laddering, acridine-orange staining, TUNEL staining, and 
FACS analysis using Annexin V and propidium iodide, showed that the flaxseed-treated 
cells were undergoing apoptosis, a type of cell suicide.  Therefore, due to its ability to 
selectively inhibit malignant cell proliferation, flaxseed oil has significant potential as an 
anti-cancer therapeutic. 
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1.0 Introduction 
Traditionally, natural products were used as medicine by indigenous populations 
to treat a broad range of diseases and ailments1,2.  In developing countries, the majority of 
people still rely on the use of traditional medicine and the use of plant sources for 
treatment as their primary healthcare3.  This translates into approximately 3.5 to 4 billion 
people worldwide3.  These traditional ways have piqued the interest of contemporary 
researchers and have encouraged in-depth analysis of plant materials commonly found as 
part of these native treatments. Historically, natural products have always provided a 
starting point and pharmaceutical companies have utilized plant extracts to produce crude 
therapeutic formulations4.  In recent years, natural products, in their naturally occurring 
state, have been at the forefront of drug discovery experiments.  Furthermore, the 
chemical diversity of natural products has led researchers to isolate and screen plant 
materials in hope of finding compounds that may possess medicinal properties4,5.   
Although many therapeutic areas have reaped the benefits of natural products and 
drug development, oncology has had the most success.  Approximately 60% of the new 
drugs intended to treat cancer were developed from a natural product source5-7.  Between 
2005 and 2010 alone, there have been a total of 19 natural product-based drugs which 
have been approved for marketing worldwide5.  In addition, many of the leading 
antitumor drugs currently in use were developed from a natural product source5,6.  One of 
the best recognized of these anti-tumour drugs is Paclitaxel (Taxol®).  Ironically, Taxus 
brevifolia Nutt. (T. brevifolia), commonly known as the Pacific Yew, was once referred 
to as the tree of death because of its toxicity to humans and wildlife, is now referred to as 
the tree of life for many cancer patients since the discovery that taxol was present in its 
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bark7,8. Paclitaxel, a mitotic inhibitor originally isolated from T. brevifolia but now 
synthesized chemically from more readily available precursors is used in the treatment of 
various cancers, including, lung, ovarian and breast cancer7-10. Paclitaxel stabilizes 
microtubules in rapidly dividing cancer cells and interferes with the normal breakdown of 
microtubules during cell division1,7-10.  Although it may be the most recognized example 
of a natural product used in modern medicine, many drugs have been derived from a 
natural product source.   
 
1.1 Traditional Use of Natural Products in Medicine 
Natural products are defined as chemical compounds or substances produced by a 
living organism or found in nature.  These compounds often have chemical properties 
that are beneficial for use in pharmaceutical drug discovery11.  A chemical compound can 
be classified as a natural product regardless if it can be prepared by total synthesis” 11.  
Natural selection and biological interactions have evolved the chemical diversity of 
naturally occurring compounds, allowing them to modulate or influence certain 
biological functions7,8.  The affinity and specificity that these natural occurring 
compounds may have with biological macromolecules make them an ideal starting point 
for drug discovery4-8. 
Historically, the medicinal use of natural products by humans has been shown to 
go back to the time of Neanderthals.  A palaeoanthropological study at the cave site of 
Shanidar, located in the Zagros Mountains of Kurdistan in Iraq, discovered pollen 
deposited within the graves of a burial sanctuary9.  These findings suggest that 
Neanderthals may have used certain plant materials for medicinal purposes over 60,000 
3 
 
years ago9.   Before the development of modern medicine, our ancestors were forced to 
depend solely on natural products for the treatments of ailments, as well as aches and 
pains.  Whether it be, to chew on herbs to relieve pain, to wrap leaves around wounds to 
prevent infections, or to create a paste from a mixture of plant materials to encourage 
faster healing, the natural remedies that have been passed down through generations are 
now grabbing the attention of researchers for their potential benefit to modern 
medicine1,10.    
It is often difficult for researchers to explain how naturally occurring plant 
compounds can have biological effects in humans.  One commonly accepted hypothesis 
includes coevolution of biological systems.  Interacting organisms that have evolved 
alongside each other often develop compounds that can interact with the biological 
processes of one another12.  The result is an increased likelihood of survival. It is survival 
of the fittest, and as these compounds evolve and become more advantageous to the host 
species, natural selection will allow for these organisms to survive12.  Some examples of 
coevolution and natural products include the toxins that plants have evolved to protect 
themselves from herbivores12.  These toxins are now isolated and used in the manufacture 
of laxatives, and used for the treatment of constipation in humans12. 
There are numerous natural products that are known to induce apoptosis, and 
these compounds which regulate apoptosis are of high medical significance, as cell death 
evasion is a hallmark characteristic of malignancy.  Apoptolidin, a macrolide originally 
isolated from Amicolatopsis sp., is an example of a natural product that selectively targets 
mitochondria and inhibits ATP enzymatic functions in several cancer cell lines13. Since 
mitochondria are the energy-producing organelles of the cell, natural products that can 
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selectively target mitochondrial functions in malignant cells are of high importance14.  In 
recent years, there has been an increase in studies that show that many of the common 
herbs and vitamins that are readily available to consumers may in fact affect 
mitochondrial activity, directly or indirectly14. With many cancer patients taking vitamins 
and supplements in conjunction with, or instead of chemotherapeutic- and radiation-
treatment plans, it is becoming more urgent to understand the chemical interactions that 
these natural products may have on malignancies, both in the presence and absence of 
prescribed anticancer drugs14.  The potential of herb and nutrient supplement interactions 
with drugs have caused many researchers to systematically evaluate the potential of 
"functional foods" in treatment plans.    
 
1.2 Flaxseed Oil Consumption 
Flax, in the form of seeds or seed-derived oil, is a “functional food” recognized 
for its exceptional nutritional value due to its high concentration of fiber-based lignans 
and large amounts of omega fatty acids15-17.  Flaxseed is one of the most important 
oilseed crops, as every part of the plant can be used commercially15-16.  Canada is the 
major exporter of flaxseed and flaxseed products, contributing about 80% of the global 
trade supply15.  Linum usitatissimum L., a member of the Linaceae family and commonly 
referred to as flaxseed, has been cultivated for food and fibers for over 30 000 years.  It is 
used in the production of paints and textiles, where the seeds are crushed for the 
extraction of oil15-16.  Linum usitatissimum is referred to as flaxseed or linseed, depending 
on whether the flax is to be used for human consumption, or for industrial purposes, 
respectively15,16.  Flaxseed is unique among oilseeds because its oil is a source of the 
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essential omega-3 fatty acid, alpha linolenic acid (ALA)15,16,18.  It is critical that humans 
incorporate foods high in ALA into their diets because the human body lacks the required 
desaturation enzymes that are necessary for inserting double bonds at the 12- and 15- 
carbons18-20.  Following ingestion, ALA is metabolically converted into the longer chain 
omega-3 fatty acids, eicosapentaenoic (EPA) and docosahexaenoic acid (DHA)18-20.  It is 
crucial to obtain sufficient amounts of EPA and DHA from the diet, since these two 
omega-3 fatty acids can partially reduce the pro-inflammatory effects of the omega-6 
fatty acid arachidonic acid18-20.  Since flaxseed oil is recognized as one of the largest 
sources of ALA, it has also been titled as a health promoting, functional food16.  
Many studies focused around flaxseed consumption have shown increased health 
benefits to patients suffering from symptoms caused by cardiovascular disease17, 
diabetes21, and cancer22.  Unfortunately, the underlying mechanisms of how flax seeds or 
flaxseed oil, influences biological processes remains a mystery.  Unsaturated fatty acids 
have previously been shown to modulate a number of lymphocyte functions14,23.  These 
functions include natural killer cell activity, cytokine release, adhesion molecule 
expression, as well as cell proliferation and cell death14,23.  The majority of studies 
focused around flax seeds and flaxseed oil have been investigated in animal models.  
Previous animal studies have shown that a diet supplemented with 10% flaxseed, 
significantly decreased tumour growth in rodent cancer models23-27.  In contrast, our 
studies focus on the direct exposure of malignant cells to flaxseed oil in an in vitro 
model.  The antioxidant properties of flaxseed oil also make it a favourable supplement 
that is often included in established treatment regimens for patients undergoing 
chemotherapy and radiation therapies.  By understanding how flaxseed oil interacts with 
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malignant cells, both in the presence and absence of chemotherapies, there is a potential 
to develop an anticancer drug or drug combination that may have minimal side effects. 
 
1.3 Functional Foods, Flaxseed and Fatty Acids 
The increased consciousness of the general population regarding healthier 
lifestyles and increased awareness of what they are consuming, has gradually changed the 
perception of foods as a physical requirement to the possibility of using foods as 
contributing factors to overall health and wellbeing29-32. Hence, functional foods are 
described as foods that provide basic nutritional requirements but also, have additional 
known health-promoting benefits31,32.  Functional foods tend to have one of two effects: 
they either enhance physiological wellness, or they reduce the risk of a particular 
disease31,32.  The concept of functional foods has been previously investigated and both 
nutritional and epidemiological studies have shown that poor diets can cause or influence 
chronic diseases, including cardiovascular disease, diabetes and cancer29-32.  Although the 
term functional food is commonly used, there are few regulations around this category.  
Some of the most popular functional foods are foods that are high in antioxidants, 
polyphenols, prebiotics and probiotics31,32.  
Flaxseed, in the form of seeds and seed-derived oil, is an example of one of these 
known functional foods.  The oil is a rich source of the omega-3 fatty acid, alpha 
linolenic acid, a fatty acid that is often lacking in Western diets.  Flaxseed and in 
particular omega-3 fatty acids, have been shown to have protective benefits against 
breast, colon and prostate cancers22.  Furthermore, studies have shown that patients who 
introduce flaxseed into their diets demonstrated signs of resistance to early stages of 
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some cancers33, reduced the risk of hormone-related cancers26,34, and diminished the rate 
of metastases of some breast cancers25.   
 
1.4 Omega-3 and Omega-6 Structures, Classification and Desaturation 
 Although the exact mechanisms to explain how flaxseed oil affects cancer rates 
and metastases are not known, many suggest that establishing an appropriate balance of 
omega-3 to omega-6 fatty acids may in part be responsible18,35.  Both omega-6 and 
omega-3 fatty acids are required for proper cellular function and human development18,35.  
Unlike some fatty acids that are capable of being synthesized within the human body, 
omega-3 alpha linolenic acid and omega-6 linoleic acid are considered essential and must 
be acquired from our diets18,22,35,36.   However, humans do possess the required enzymes 
that allow for elongation of alpha linolenic and linoleic acid and their conversion to the 
longer chain counterparts, docosahexaenoic acid and arachidonic acid18,22,35,36.  This 
conversion is inefficient and the rate of synthesis is incapable of sustaining daily 
requirements35.  Fatty acids are mainly present in the body as triacylglycerols, a complex 
that is formed by three fatty acids attached to a glycerol backbone18,35.  Although fatty 
acids can vary from short two carbon chains to as long as eighty carbon chains, the most 
common lengths found in foods tend to be between fourteen and twenty-two carbon 
atoms18,35.  A saturated fatty acid chain is one that contain only a single carbon-carbon 
bond at each position, which results in a chain linked to the maximum number of 
hydrogen atoms18,35.  If the chain contains at least one double bond, then the fatty acid is 
called unsaturated.  Polyunsaturated fatty acids possess multiple double bonds between 
carbon atoms18,35.  The positioning of the double bonds and the position of its hydrogen 
8 
 
atoms determines the structure of the fatty acid18,35.   If at the double bond both hydrogen 
atoms are positioned on the same side of the carbon chain, then it is described as a cis 
fatty acid18,35.  However, if the hydrogen atoms are positioned on opposite sides of the 
double bond, then the fatty acid is described as trans18,35.  Cis configurations tend to be 
the most popular in unprocessed foods, whereas trans configurations are common in 
ruminant meats and milk, as well as in unsaturated oils that have undergone 
hydrogenation18,35. 
 Omega fatty acids are further classified and grouped into fatty acid families by the 
number of carbon atoms within the chain, and most importantly by the placement of the 
first double bond37. If the first double bond is located between the third and fourth bond 
position from the methyl terminal end, then the fatty acid is classified an omega-3 fatty 
acid37 (Figure 1).  In the same sense, if the first double bond is placed between the sixth 
and seventh bond position from the methyl terminal end, then the fatty acid is classified 
as an omega-6 fatty acid37 (Figure 1).   Docosahexaenoic acid (22:6 ω-3) is therefore a 22 
carbon chain with 6 double bonds, with the first double bond situated at the third-fourth 
carbon position from the methyl terminal end, and is hence an omega-3 fatty acid37.  
Arachidonic acid (20:4 ω-6) is a 20 carbon long chain containing 4 double bonds, with 
the first double bond located at the sixth-seventh carbon bond position from the methyl 
terminal end, and hence therefore an omega-6 fatty acid37.  The metabolic pathways that 
describe the synthesis of omega-3 and omega-6 fatty acids are similar, with both 
consisting of desaturation and elongation steps18,35,37.  The byproduct of each step 
changes dramatically depending on which class of omega fatty acids commences the 
pathway.   
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metabolically converts the omega-6 fatty acid linoleic acid to dihomo-γ-linolenic acid via 
γ-linolenic acid, while its competing omega-3 fatty acid, alpha linolenic acid is converted 
to eicosatetranoic acid, via octadecatetraenoic acid18,35.  The Δ5-desaturase enzymes 
metabolically convert the omega-6 fatty acid dihomo-γ-linolenic acid to its end product 
arachidonic acid, while promoting conversion of the omega-3 fatty acid eicosatetraenoic 
acid to both eicosapentaenoic acid and docosapentaenoic acid18,35.  Docosahexaenoic 
acid, the end product of the omega-3 fatty acid desaturation pathway, is metabolically 
converted from docosapentaenoic acid through two independent pathways using Δ4-
desaturase, or Δ7-elongase and the additional Sprecher pathway 18,35. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Competing desaturation and elongation pathway of the omega-3 and 
omega-6 fatty acids20. 
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1.5 Omega-3 versus Omega-6 Functions 
The metabolites from both the omega-3 and the omega-6 pathways have several 
functions.  They can influence cell viability and functionality through eicosanoid 
regulation, receptor interactions, membrane fluidity and/or gene expression40. 
Arachidonic acid and eicosapentaenoic acid are both strong regulators of various families 
of eicosanoids, a family of diverse hormone-like agents that include prostaglandins, 
prostacyclins, leukotrienes and thromboxanes35. The various eicosanoids can act as 
signaling molecules with specific receptor-signaling cascades that can have rapid and 
profound effects on physiology and immune functions.  Eicosanoids derived from omega-
6 fatty acids tend to be pro-inflammatory, whereas eicosanoids derived from omega-3 
fatty acids tend to be anti-inflammatory35,40.  Arachidonic acid derived thromboxane 
TXB2 and eicosapentaenoic acid derived thromboxane TXB3 are just one example of the 
difference of eicosanoid functions derived from omega-6 versus omega-3 fatty acids.  
TXB2 is a vasoconstrictor and platelet activator through TP-α receptors.  In contrast, 
TXB3 impedes TXB2 functions by inhibiting TXB2-mediated platelet aggregation, and 
increasing vasodilation40.  
Fatty acids can also be major components of cellular membranes.  Membrane 
fluidity is highly influenced by the presence of omega-3 or omega-6 fatty acids.   This is 
due in part to the large structural differences in the acyl chains between the two PUFA 
families40.  Membrane fluidity can greatly affect cellular functions as it affects membrane 
permeability, and secondarily protein trafficking.  Researchers have previously shown 
that the omega-3 fatty acid, docosahexaenoic acid, regulates phosphotidylserine by 
signalling it to accumulate40.  The accumulation of phosphotidylserines in the cytosolic 
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side of the plasma membrane can facilitate stimulation and membrane translocation of 
certain protein kinases40.  Akt is an example of one of the protein kinases that can be 
activated by accumulation of cytosolic leaflet phosphotidylserines and results in an 
enhanced cell survival signal41.  Since Akt/PI3k is a pro-survival pathway, the 
accumulation of Akt at the cellular membrane may in fact leave mitochondria vulnerable 
to proapoptotic ligands.  Fukui et al. (2013)41 have previously shown that omega 3 fatty 
acids are capable of causing mitochondrial reactive oxygen species (ROS) accumulation 
in human breast cancer cells.  The accumulation of ROS in turn activates apoptosis 
through Caspase 841.  Both the intrinsic and extrinsic apoptotic pathways crosstalk 
through Caspase 841. 
In vitro studies have been performed to measure prostate cancer cell growth in the 
presence of omega-3 and omega-6 fatty acids39.  Researchers found that treatment with 
omega-3 fatty acids inhibited prostate tumourigenesis in tissue culture models, while the 
cells treated with omega-6 fatty acids showed increased rates of cellular proliferation39.    
These findings are not unique to prostate cancers, and researchers have repeated these 
studies in breast cancer cells as well.  In animal studies, mice fed diets high in omega-6 
fatty acids, primarily from corn and safflower oils, had increased mammary tumour 
proliferation and higher rates of metastases42-44, while the mice fed diets high in omega-3 
fatty acids primarily from fish oils, showed lower rates of metastases and decreased 
mammary cell proliferation42-44.  Natural products that are capable of interfering with cell 
proliferation or inducing apoptosis are of high importance in oncologic research since 
they promote a means to interfere with tumour growth. 
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1.6 Natural Products, Cell Growth and Cell Death 
  It is well known that many of the compounds that are currently used to treat 
human diseases are derived from plant, microorganisms or animal sources1.  With over 
10 million new cases of cancer emerging yearly, it is the second leading cause of death in 
North America1.  Oncology is one field that could benefit from better treatments as well 
as preventive options1. Drug discovery from medicinal plants has already played a critical 
role in the treatment of cancer and approximately 60% of the drugs currently being used 
in the field of cancer were developed from a natural source5.  Cancer treatments usually 
regulate tumour growth in two specific ways based on the hallmark characteristics of 
cancer.  These include interference with cell growth and increased susceptibility to cell 
death.  The normal cell cycle is regulated by increases and decreases in specific cyclin 
levels in a tightly regulated manner45,46.  The relative change in cyclin levels ensures 
proper DNA replication, and consequently cellular division.  There are four phases of the 
cell cycle required for cell proliferation: G1, S, M and G245,46.  In S phase, the DNA is 
replicated, while in M phase the newly-replicated DNA is segregated, and the cell 
physiologically divides into two daughter cells.  These two phases are separated by gap 
phases referred to as G1 and G245,46.  Cells can also withdraw into a third gap phase 
referred to as G0, where cell cycle division stops.  This third gap phase can be a 
reversible state, and usually occurs as a result of high cell density, or a lack in nutrient 
availability in cultured cells45,46.  In addition, cells can enter an irreversible state of 
withdrawal from the cell cycle45,46.  This state occurs in response to terminal 
differentiation or senescence45,46.  The cyclin-dependent kinases and the cyclins control 
the cell cycle and ensure regulated progression through the cell cycle45,46.  The transition 
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of one phase to another is monitored by checkpoints.  If the normal progression through 
the cell cycle is detected as incorrect by a mechanism sensor at the checkpoint, the cell is 
inhibited from progressing through the cycle to the next phase, and remains arrested until 
the checkpoint signal is corrected45,46.  Malignancies are a result of mutations in somatic 
cells and mutated genes tend to directly or indirectly affect the cell cycle45.  For normal 
cells, mitogenic stimulation is required for the cell to enter the cell cycle45,46.  However 
malignant cells frequently have constitutively active growth signaling pathways 
(oncogene activation) and are able to enter and remain in cycle permanently, 
consequently resulting in the formation of tumours45.  Furthermore, malignant cells are 
often plagued with faulty DNA repair and ineffective checkpoints which do not prevent 
proliferation of damaged or defective cells45.  These malfunctions intensify the genetic 
instability and encourage a vicious cycle of uncontrolled cell proliferation45.  Therefore, 
targeting deregulated components in the cell cycle by pharmacological treatment is one 
ideal strategy in cancer therapies45.  Antineoplastic agents are drugs that are designed to 
target and inhibit the cell cycle by disrupting the necessary mechanisms for the formation 
of mitotic spindles, and for the replication of DNA and regulation of the nucleotide 
synthesis machinery45,46.  Treatment regimens for patients undergoing chemotherapies 
tend to include combinations of drugs designed to target different stages of the cell cycle.  
There is an additive anti-tumour benefit of multi-targeted cell cycle chemotherapeutic 
agents, and as long as the apoptotic machinery is functional, the cell is forced to correct 
its cycle, or to initiate apoptosis46. 
The evasion of cell death, or apoptosis a type of cell suicide, is a second hallmark 
characteristic of cancer.  On average, each person has 50 billion cells that die each day.  
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In one year, it is suggested that the average person proliferates and destroys a mass of 
cells equivalent to their body size47.  It is no longer surprising to see the link between cell 
death evasion and the development of cellular hyperplasia, and consequently malignancy.  
Furthermore, the exposure to known, as well as currently un-identified carcinogens is 
becoming increasingly common from the environment.  Carcinogens are known to cause 
cancer and enable these transformed cells to evade apoptosis, in turn promoting 
tumourigenesis47. There are two pathways in mammals and other vertebrates that control 
apoptosis: the intrinsic pathway which is regulated by the Bcl-2 family of proteins and 
primarily affects mitochondrial function, and the extrinsic pathway that requires an 
external signal transduced through a death receptor of the TNFα receptor family47-49 
(Figure 3).  In the intrinsic pathway, the Bcl-2 proteins are activated in response to 
intracellular stimuli47-49. These stimuli can range from developmental cues, cytotoxic 
stress, nutrient and growth factor deprivation, infection, DNA damage, and hypoxia47-49.   
These stimuli disrupt proapoptotic Bcl-2 proteins found in the mitochondrial membranes, 
causing increased mitochondrial membrane permeabilization and the release of 
intramembrane proteins, including cytochrome C and Smac/DIABLO50.  The release of 
these proteins into the cytosol, promotes an activation cascade called the apoptotic 
pathway.  In particular the release of cytochrome c allows the formation of a structure 
called the apoptosome complex that includes Apaf-1 and caspase-949.  The newly formed 
apoptosome complex activates caspase-3 which is a wide specificity protease frequently 
thought of as the “executioner”49.  Following activation, caspase-3 cleaves and 
proteolytically degrades a host of intracellular proteins, and ultimately produces cellular 
and biochemical changes necessary for apoptosis49.   
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Figure 3 The Intrinsic and Extrinsic Apoptotic Pathways50.  
 
In the extrinsic pathway, extracellular signals are transduced through activation of 
receptors in the cellular membrane as specific ligands such as Fas ligand (FasL), tumour 
necrosis factor α (TNFα), or tumour necrosis factor-related apoptosis-inducing ligand 
(TRAIL) binds to the corresponding death receptor51(Figure 3).  The binding of a ligand 
to its receptor triggers aggregation of cytosolic receptors and adaptor proteins at the cell 
membrane51.  For example, the aggregation of Fas-associated death domain protein 
(FADD) and initiator caspase 8 creates a death-inducing signal complex known as DISC, 
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resulting in the activation of caspase 851.  Newly activated caspase 8 is able to interact 
with caspase 3, an effector caspase, and begin the caspase activation cascade51.  
Furthermore, caspase 8 cleaves associated proteins BID and tBID on the mitochondrial 
membrane and facilitates the release of cytochrome c and initiates the intrinsic apoptotic 
pathway51. Although the initial signal and transduction is uniquely different in each 
pathway, the pathways converge at the activation of downstream effector caspases.  
Natural product agents capable of inducing apoptosis through the apoptotic pathways 
could have an additive effect for the current chemotherapeutic agents which affect cancer 
cells through other pathways such as cell cycle dysfunction. 
 
1.7 Natural Products and Chemotherapy 
There are four major classes of plant-derived anti-cancer drugs: vinca alkaloids, 
epipodophyllotoxins, taxanes and camptothecin quinolone alkaloid derivatives1(Figure 
4).  Vinca alkaloids inhibit cellular proliferation through microtubular dysfunction during 
mitosis which ultimately leads to apoptosis1.  The vinca alkaloids specifically induce 
destabilization through tubulin binding14.  This binding in turn prevents polymerization14.  
Vinblastine and Vincristine are two examples of Vinca alkaloids.  Both are active 
compounds isolated from the Madagascar periwinkle, Catharanthus roseus (L.) G. Don, 
and are most commonly used in the treatments of leukemias52.  Researchers have also 
developed semi-synthetic versions of Vinblastine and Vincristine, which are referred to 
as Vinorelbine and Vindesine52.  These semi-synthetic counterparts showed success in the 
treatment of leukemia, lymphomas, breast cancer and lung cancer, all while exhibiting 
lower levels of toxicity in animal models52.   
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Another group of chemotherapeutic agents belong to the class of Taxanes.  
Paclitaxel was isolated from the bark of the Pacific Yew54.  Various deritatives of 
Paclitaxel have been developed to combat solubility and toxicity issues. Paclitaxel, as 
well as its derivatives are anti-mitotic drugs54.  Taxane drugs bind to polymerized 
microtubules resulting in failed progression through the mitotic phases ultimately causing 
cell death52,54.  This class of chemotherapeutic agents is often used in the treatment for 
patients diagnosed with either breast or ovarian cancer52,54.  Taxanes function by 
stabilizing GDP interaction with tubulin in the microtubule and prevents microtubule 
lengthening or shortening as required to segregate the mitotic spindles during separation 
of the chromatids during mitosis. This consequently causes cell cycle progression to 
fail52,54.  Although the vinca alkaloids and taxanes both affect microtubules function, 
taxane agents function as mitotic inhibitors, wherease the vinca alkaloids destroy the 
mitotic spindles52,54. 
The fourth class of drugs are the camptothecin quinoline alkaloid derivatives.  
Isolated from the bark of Camptotheca acuminate, camptothecin, is a cytotoxic 
alkaloid52.  Camptothecin inhibits DNA Topoisomerase I functions resulting in 
replication and transcription dysfunction52.  Since camptothecin is severely toxic as well 
as poorly soluble, various analogs were synthesized to optimize the anticancer properties 
of camptothecin while minimizing the side effects52.  With so many of the presently used 
chemotherapeutic agents being derived from a plant source, there is hope that a stronger 
and more efficient anti-cancer agent has yet to be isolated.         
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1.8 Proposal 
The two most common types of treatments available to cancer patients remain 
chemotherapy and radiation therapy. These treatments often damage the normal healthy 
cells within the body resulting in monstrous side effects.  Patients often experience 
increased nausea and fatigue.  Cancer patients are also found to describe their state of 
mind as lethargic while undergoing treatment.  The goal of new cancer treatments are 
shifting to concentrate on minimizing side effects, while increasing the efficiency in 
treatment targets.  Secondly, clinical cancer research is also gradually shifting from 
reactive responses, to concentrating on cancer preventive measures.  It is a combination 
of these two goals that are promoting the importance of healthy choices through the 
incorporation of functional foods into the average diet.  Our choices today have the 
potential to influence our future medical profiles, since bioactive food components have 
the ability to interact with genomic, proteomic, and metabolic factors.   
With its increasing popularity, flaxseed has been tested on various diseases 
including obesity, cardiovascular to even diabetes.  For each disease, studies have shown 
that flaxseed is beneficial in combating the symptoms, as well as reversing the effects of 
these individual diseases.  Unfortunately, the research surrounding flaxseed oil and its’ 
effect on cancer cells has been limited to in vivo models and therefore it remains unclear 
how flaxseed oil, or its’ individual components may interact at the cellular level.  
We propose to look at the effects of flaxseed oil, the largest plant source of omega 
3 fatty acids, on the aggressive murine melanoma cell line B16-BL6 using a series of in 
vitro studies.  Furthermore, we propose to look at the metabolic changes in flaxseed oil 
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following acid metabolism by exposure to B16-BL6 cells using GC/MS analysis.  
Flaxseed oil has the potential to be a key component of current cancer treatment regimes.   
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2.0 Material and Methods 
 
2.1 Tissue Culture 
The B16-BL6 (murine melanoma), [American Type Culture Collection, 
Manassas, VA] were maintained in Dulbecco’s Modified Essential Medium (DMEM, 
Hyclone, Logan, UT) supplemented with 10% fetal bovine serum (Hyclone), 100 µg/ml 
streptomycin, and 100 U/ml penicillin (Invitrogen, Burlington, ON). Cells were incubated 
at 37 ºC in 5% CO2.  For experiments, cells were treated with media containing one of the 
following plants oils: flaxseed, sunflower, canola, olive, peanut, sesame, and grapeseed.  
Oils were purchased commercially.  Plants oils were mixed directly in media.  Low dose 
treatments consisted of 3 µl of plant oil per ml of media and high dose was 9 µl per ml of 
media.  All experiments were run in triplicate for each assay. 
  
2.2 Gas Chromatography/Mass Spectrometry of Plant Oils 
Omega-fatty acid chromatograms were determined for seven plant oils and three 
brands of flaxseed oil using Gas Chromatography Mass Spectrometry (GC/MS).  
Analysis of plant oils and the 37 fatty acid methyl ester standards kit (Supelco’s standard 
in CH2Cl2) were analyzed on a DB-WAX column (30 m x 0.25 mm x 0.25 um) with a 5 
m deactivated fused silica guard column of same dimensions with the following program 
rate: 50°C, 1 min., 25°C/min. to 200°C, 3°C/min. to 230°C, 8 min.  Major peaks were 
determined by comparing retention times of the plant oil chromatograms with the known 
retention times of the 37 fatty acid methyl ester standard kit (FAME kit).  Table 1 lists the 
fatty acid composition of each of the analyzed plant oils. 
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Table 1 Fatty Acid Percentages of the Analyzed Plant Oils 
Oil Alpha Linolenic Acid Linoleic Acid Oleic Acid 
Flaxseed 57% 16% 18% 
Sunflower 4% 65% 16% 
Canola 9% 20% 61% 
Sesame 5% 41% 44% 
Peanut 5% 32% 48% 
Grapeseed < 1% 69% 16% 
Olive < 1% 8% 75% 
 
 
2.3 Trypan Blue Survival Analysis 
Trypan blue survival assay was used to determine the effects of plant oils on cell 
proliferation in B16-BL6 cells.  Cell cultures were prepared at 3 x 105 cells/ml 
confluence on day 0, and B16-BL6 cells were treated with plant oils at low dose (3 µl of 
plant oil per ml of media) or high dose (9 µl of oil per ml of media), and compared to 
untreated controls.  The plant oil treatments remained in the treated media throughout the 
length of the experiment.  Experiments were 5 days long, and cell counts were recorded 
for each treatment at 24 hr intervals.  Treated B16-BL6 plates were harvested at timed 
intervals using 0.25% trypsin-EDTA and centrifuged at 1,500 rpm for 10 min.  Following 
harvest, cell pellets were resuspended in PBS, pH 7.4, and incubated with 15 µl of 
Trypan blue.  Stained samples were placed on a hemacytometer and cell counts of clear 
(live) and blue stained (dead) were recorded for each sample. Experiments were repeated 
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in triplicate and statistical analysis of cell counts was performed by ANOVA using Graph 
Pad Prism Software. 
 
2.4 Cell Viability by Methyl Tetrazolium Blue (MTT) 
Viability of cells treated with plant oils was determined by a methyl tetrazolium 
bromide (MTT) reduction assay.  Approximately, 3000-5000 cells per well were plated in 
a 96-well plate and incubated overnight with 5% CO2 at 37 ºC to allow sufficient time for 
cells to adhere.   B16-BL6 cells were treated with media, or low dose (3 µl/ml media), or 
high dose (9 µl/ml media) of one plant oil 24hrs following plating.  Plant oil treatment 
remained on cells throughout the length of the 5 day experiment.  For solvent 
experiments, treatments were prepared by mixing plants oils with one solvent (70% 
Ethanol, DMSO, hexane and dichloromethane) at the previous mentioned concentrations 
for low and high dose treatments.  Solvent preparations were vortexed, incubated for 24 
hrs and used to treat B16-BL6 cells.  Treatment with solvent only was used as controls.  
At 24 hr intervals, 10 µl of MTT solution was added to each well of one replicate plate 
using a multichannel pipettor at a final concentration of 0.5 mg/ml.  Plates were 
incubated at 37 ºC at 5% CO2 for 3 hrs.  200 µl of dimethyl sulfoxide (DMSO) was added 
to each well following the incubation period.  To ensure full dissolution of purple 
formazan, cells were repeatedly pipetted.  The absorbance was measured at 540 nm using 
a Titertek Multiskan® MCC/340 plate reader.  Experiments were repeated in triplicate 
and statistical analysis of single concentration points was performed by ANOVA using 
Graph Pad Prism Software.  For recovery experiments, flaxseed oil treated media was 
removed from wells and replaced with fresh media at timed intervals. 
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2.5 FACS Analysis: Annexin V and Propidium Iodide Stain 
Cell proliferation and cell death were determined by FACS analysis following 
annexin V and propidium iodide staining.  B16-BL6 cells were treated with media, or low 
dose (3 µl/ml media), or high dose (9 µl/ml media) of one plant oil 24 hrs following 
plating.  Treated B16-BL6 plates were harvested at timed intervals using 0.25% trypsin-
EDTA and centrifuged at 1,000 rpm for 10 min.  Cells were washed with 1 ml of PBS 
and transferred to Eppendorf tubes.  Cells were centrifuged at 1,000 rpm for 2 mins and 
supernatant discarded.  Cells were blocked in PBS containing 1% FBS for 45 mins.   
Following blocking, cells were washed with 1 ml PBS, centrifuged at 1,000 rpm for 2 
mins and supernatant was removed and discarded.   Cells were treated with 5µl of 
annexin V-FITC stain and incubated for 1 hr.  Following incubation, cells were washed 
with 1 ml PBS, centrifuged at 1,000 rpm for 2 mins and supernatant was removed and 
discarded.  Cells were treated with 5 µl of propidium iodide stain and incubated for 30 
mins.  Samples were filtered through a syringe to avoid clumping.  Experiments were run 
in triplicate and Annexin V-FITC binding and propidium iodide staining were analyzed 
by flow cytometry. 
 
2.6 Fluorescence Microscopy: Acridine Orange, Ethidium Bromide, TUNEL, 
Lysotracker and Mitotracker 
 
Cell death was determined by fluorescence microscopy using the following 
cellular stains: acridine orange and ethidum bromide, TUNEL, and Lysotracker. Cells 
were plated at 30% confluence on coverslips in 6-well plates and incubated overnight 
with 5% CO2 at 37 ºC to allow sufficient time for cells to adhere.  B16-BL6 cells were 
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treated with media, positive controls (Camptothecin, Cyclohexamide, Rapamycin or UV 
treated), low dose (3 µl/ml media) plant oil, or high dose (9 µl/ml media) plant oil 24 hrs 
following plating.  Treated B16-BL6 plates were harvested at timed intervals using 
0.25% trypsin-EDTA and centrifuged at 1,000 rpm for 10 min.  Cells were washed with 1 
ml of PBS, fixed in 1ml of 2% paraformaldehyde in PBS and incubated for 5 mins.  Cells 
were washed twice with PBS and incubated with one of the following fluorescence 
microscopy stains: acridine orange and ethidum bromide, TUNEL, Lysotracker and 
Mitotracker.  Experiments were run in triplicate and cells were photographed by confocal 
microscope. 
 
2.7 Metabolism Experiment 
Omega-3 fatty acid metabolism by B16-BL6 cells was determined by a novel 
experimental approach.  B16-BL6 cells were plated at 30% confluence in large 100 mm 
tissue culture plates and incubated overnight with 5% CO2 at 37 ºC to allow sufficient 
time for cells to adhere.  Cells were treated with media, or low dose (3 µl/ml media), or 
high dose (9 µl/ml media) flaxseed oil 24 hrs following plating.   Control media and 
flaxseed oil treated media were removed from tissue culture plates at 24 hr intervals and 
used for treatment of a set of five 96-well plates containing B16-BL6 cells which had 
been previously plated, and would be used in part two of this experiment.   This process 
was repeated at each 24 hr interval and a new set of five 96-well plates was produced for 
each day of the experiment.  In part two of this experiment, 24 hrs following initial 
treatment of the 96-well plate with the reused media from the initial experiment, one 96-
well replicate plate from each set of experimental days was treated with MTT.  
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Experiments were repeated in triplicate and statistical analysis of single concentration 
points was performed by ANOVA using Graph Pad Prism Software.   
 
2.8 Gas Chromatography/Mass Spectrometry Analysis of Cellular Membranes 
Cells were plated in three 100 mm dishes for each treatment and incubated 
overnight with 5% CO2 at 37 ºC to allow sufficient time for cells to adhere.  B16-BL6 
cells were treated with media, low dose (3 µl/ml media) plant oil, or high dose (9 µl/ml 
media) plant oil 24 hrs following plating.  Cells were lysed with 1.5 ml of methanol 
(OPTIMA grade, Cat # A454-4, Fisher) with 0.01% BHT (2,6-Di-tert-butyl-4-
methylphenol, Cat # B1378, Aldrich) using a cell scraper.  Cells were collected in a glass 
tube, sealed and sent to the CCARM laboratory in Winnipeg, Manitoba for GC/MS 
analysis.  The fatty acid composition of B16-BL6 cellular membranes was analysed by 
gas chromatography (GC) using a Varian 450-GC Gas Chromatograph with an FID 
detector (Varian, Lake Forest, CA) and a GC capillary column (length 100 m, diameter 
0.25 mm and film thickness 0.25 μm; Varian, Lake Forest, CA)55,56.   
28 
 
3.0 Results 
3.1 GC/MS Fame Profiles of Plant Oils 
 Omega fatty acid profiles of six plant oils and three brands of flaxseed oil were 
determined by GC/MS.  Major omega fatty acids were identified by comparing retention 
times of the major peaks found in the oil samples to the known retention times (tR) of 
omega fatty acids from the 37 fatty acid methyl ester standards kit (FAME stds) (Figure 
5).  Major Peaks found in the plant oils included methyl palmitate (tR 9.94 min), methyl 
stearate (tR 12.02 min), methyl oleate (tR 12.31 min), methyl linoleate (tR 12.91 min), and 
methyl linolenate (tR 13.84 min).  Peanut, canola, sesame and olive oils had a major peak 
for methyl oleate at 12.31 min retention time.  Sesame, grapeseed and sunflower oils had 
the major peak for methyl linoleate at 12.91 min retention time.  Flaxseed oil had the 
major peak for methyl linolenate at 13.84 min retention time (Figure 5).  GC/MS 
produced similar omega fatty acid profiles for all three brands of flaxseed oil.  Although 
there were some noticeable differences in the sizes of the detected peaks, all three 
flaxseed oil brands had methyl palmitate (tR 9.94 min), methyl stereate (tR 12.02 min), 
methyl oleate (tR 12.31 min), methyl linoleate (tR 12.91 min) and the most significantly 
detected methyl linolenate (tR 13.84 min) (Figure 6). 
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Figure 5  GC/MS Chromatograms of the oils tested and analysis of the FAME (fatty  
acid methyl esters) standards.  A-Fame Stds, B-Peanut, C-Canola, D-Sunflower, E- 
Flaxseed, F-Sesame, G-Olive and H-Grapeseed.   
 
Analysis of plant oils and the 37 fatty acid methyl ester standards kit (Supelco’s standard 
in CH2Cl2) were analyzed on a DB-WAX column (30 m x 0.25 mm x 0.25 um) with a 5m 
deactivated fused silica guard column of same dimensions with the following program 
rate: 50°C, 1 min., 25°C/min. to 200°C, 3°C/min. to 230°C, 8 min.  Major peaks include: 
methyl palmitate (tR 9.94 min), methyl stearate (tR 12.02 min), methyl oleate (tR 12.31  
min), methyl linoleate (tR 12.91 min), and methyl linolenate (tR 13.84 min).  
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Figure 6 GC/MS Chromatograms of the three brands of flaxseed oil. 
Analysis of three brands of flaxseed oil (A- Life Brand, B- Swiss Brand and C-Webber 
Brand) were analyzed on a DB-WAX column (30 m x 0.25 mm x 0.25 um) with a 5 m 
deactivated fused silica guard column of same dimensions with the following program 
rate: 50°C, 1 min., 25°C/min. to 200°C, 3°C/min. to 230°C, 8 min.  Major peaks include: 
methyl palmitate (tR 9.94 min), methyl stearate (tR 12.02 min), methyl oleate (tR 12.31 
min), methyl linoleate (tR 12.91 min), and methyl linolenate (tR 13.84 min). 
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3.2 The effects of plant oils on cell proliferation in B16-BL6 cells 
The effect of plant oils on proliferation of the aggressive murine melanoma cell 
line B16-BL6 was determined using the MTT cell viability assay.   A total of seven 
different oils containing high concentrations of omega fatty acids, including flaxseed oil, 
olive, sunflower, canola, sesame, peanut and grapeseed, which were previously 
characterized by HPLC 38 and GC/MS analysis for fatty acid profiles, were used to treat 
B16-BL6 cells (Figure 5).  Although all seven oils contain various amounts of omega-3, -
6 or -9 fatty acids, only treatment with flaxseed oil decreased the growth of the 
aggressive murine melanoma cell line B16-BL6 (p < 0.05 ) (Figure 7) .  Treatment of 
B16-BL6 with each of the other six characterized oils showed no significant change in 
cell growth  starting at 48 hrs post treatment (p< 0.001) (Figure 7).   Furthermore, this 
decrease in cell growth in response to flaxseed oil treatment was dose dependent.  
Treatment with high dose flaxseed oil (9 µl/ml of media) had significantly more cell 
growth inhibition when compared to low dose flaxseed oil (3 µl/ml of media).  
Significant changes in cell growth were detected at day 3 for low dose flaxseed oil 
treatment and as early as day 2 for high dose flaxseed oil treatment.  For both doses, cell 
viability continuously decreased over the length of the experiment.  
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Figure 7 The effect of plant oils on cell viability of the aggressive murine melanoma 
B16-BL6 using MTT assays 
 
B16-BL6 cells treated with either low dose (3 µl/ml) of plant oils (A-sunflower, flaxseed, 
sesame, canola B-peanut, grape and olive) or high dose (9 µl/ml) of plant oils (C-
sunflower, flaxseed, sesame, canola B-peanut, grape and olive) in culture media starting 
on day 0.  Control represents treatment with culture media only.  The cells were treated 
with the indicated oils at low dose (3µl/ml) and high dose (9µl/ml) on day 0 and 
maintained for the duration of the experiment.  Each day of treatment, for 5 days, the 
number of cells in each well of the plate was determined using the MTT assay.  
 (** = p < 0.01) 
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3.3 Flaxseed oil treatment induces apoptosis in B16-BL6 cells 
The induction of apoptosis was determined by investigating cellular 
morphological changes on the confocal microscope using acridine-orange and ethidium 
bromide (Figure 8).  Cells were plated onto coverslips in 6-well tissue culture plates.  
Following a 24 hr incubation period, cells were treated with either low dose (3 µl/ml of 
media) or high dose (9 µl/ml of media) flaxseed oil and compared to untreated controls or 
the positive control cyclohexamide.  The untreated controls had background levels of 
acridine orange stain present and minimal ethidium bromide staining.  These results are 
indicative of viable B16-BL6 cells.  The positive control cyclohexamide had increased 
levels of ethidium bromide staining at 24 hrs, suggesting changes in cell viability and 
potentially increased apoptosis, a type of cell death often described as cell suicide.  Low 
flaxseed oil treatment at 24 hrs had minimal detection of ethidium bromide. This finding 
suggests that 24 hrs may be too short of a time period for cells to undergo apoptosis 
following exposure to low doses of flaxseed oil treatment.  However, at 48 hrs there was 
significant increases in ethidium bromide stain in the low dose flaxseed oil treated cells.  
Furthermore, at 48 hrs apoptotic bodies could also be detected within the cells.  These 
apoptotic bodies can be visualized in the high dose flaxseed oil treatments as early as 24 
hrs following treatment.  At 48 hrs, cells treated with flaxseed oil had significant amounts 
of apoptotic bodies as well as high detection of ethidium bromide in the cells.  For all 
four flaxseed oil conditions, changes in cellular morphology including membrane 
blebbing can be visualized in the white light microscopy pictures (Figure 8).   
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Figure 8 Apoptosis analysis by acridine orange and ethidium bromide staining of 
flaxseed oil treated B16-BL6 cells 
 
B16-BL6 cells were grown on slide coverslips and treated with either low dose (3 µl/ml) 
or high dose (9 µl/ml) flaxseed oil treatments over 48 hrs, and compared to the negative 
untreated controls and the positive cyclohexamide controls. (A-24 hr untreated negative 
controls, B-6 hr positive cyclohexamide treated controls, C-24 hr low dose flaxseed oil, 
D-48 hr low dose flaxseed oil, E-24 hr high dose flaxseed oil and F-48 hr high dose 
flaxseed oil.   Significant morphological changes such as membrane blebbing are visible 
in all flaxseed oil treated conditions (C,D,E and F).  Apoptotic bodies are present in low 
dose 48 hr flaxseed oil treated cells (D) and in high dose 24 hrs (E) and 48 hrs (F) 
flaxseed oil treated cells. 
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Apoptosis and DNA damage following flaxseed oil treatment was further 
investigated using TUNEL, a stain that utilizes terminal deoxynucleotidyl transferase 
(TdT) to label dUTP nick ends (Figure 9).  B16-BL6 cells were cultured onto coverslips 
and treated with low dose or high dose flaxseed oil or sunflower oil treatments.  These 
treated cells were then compared to the negative untreated controls and the positive 
camptothecin treated control.  The untreated control and all conditions of sunflower oil 
treated cells showed no signs of TUNEL stain above the background level detections 
(Figure 9).  These findings indicate that untreated controls as well as the sunflower 
treated cells do not have significant DNA damage and therefore are not undergoing 
apoptosis.  At 24 hrs, the positive control camptothecin did have slightly increased 
TUNEL staining, a positive marker for DNA strand breaks and early apoptosis.  Positive 
brightly stained points were detected in every flaxseed oil condition to some degree.  The 
TUNEL stain was dose-dependent as well as time dependent for the flaxseed oil 
treatments, with the brightest stains in respect to DNA damage detected in the high 
flaxseed oil dose at 48 hrs (Figure 9).  This finding supports the idea that the omega-3 
rich flaxseed oil is capable of inducing apoptosis in B16-BL6 cells, while the omega-6 
rich sunflower oil is not (Figure 9).  Furthermore, annexin-V-FITC was used to determine 
the percentage of cell death in B16-BL6 cells following flaxseed oil treatment (Figure 
10).  Cells were treated with low dose or high dose of flaxseed oil or sunflower oil and 
compared to untreated negative controls and positive controls following 24 hrs and 48 hrs 
time periods.  Cells treated with low dose flaxseed oil had significantly higher detection 
of annexin V-FITC antibody at 48 hrs with 32% of its cell population detected for 
positive stain and 53% of its cell population stained positive at 72 hrs (Figure 10-C).  The 
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untreated negative controls had approximately 14% of its cell population stain positive 
for annexin V-FITC  at 24 hrs, 48 hrs and 72 hrs time points (Figure 10-B).  The cells 
treated with high dose flaxseed oil had the largest populations of positive stained annexin 
V-FITC at 52% and 45% for the 24 hr and 48 hr time points, respectively (Figure 10-D).   
The cells treated with high dose flaxseed oil at 72 hrs had fully compromised cellular 
membranes that the entire cell population was detected as positively stained at 98% 
(Figure 10-D).  These findings further support our previous results that flaxseed oil at low 
dose and as early as 24 hrs is capable of inducing apoptosis in B16-BL6 cells.  Sunflower 
oil treated cells did not show significant increases in annexin V-FITC detection at both 
low dose and high dose treatments for all three time points (Figure 10-E and F).  This 
finding is indicative of viable of cells and supports our previous findings that sunflower 
oil does not induce apoptosis in B16-BL6 cells. 
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Figure 9 Early stage apoptosis is detected by TUNEL stain in B16-BL6 cells 
following flaxseed oil treatment. 
 
B16-BL6 cells grown on coverslips were exposed to either low dose (3 µl/ml) or high 
dose (9 µl/ml) of flaxseed oil or low or high dose sunflower oil in culture media starting 
on day 0.  The negative control represents treatment with only culture media, while the 
positive controls are cells exposed to 10-6 M camptothecin.  Cells were cultured in the 
presence of the indicated agents for 24 hr or 48 hr and then fixed and stained with 
TUNEL staining kit following the manufacturer’s instructions. 
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Figure 10  Cell death in B16-BL6 cells determined by annexin V-FITC staining 
following flaxseed oil treatment. 
 
B16-BL6 cells grown in medium tissue plates and exposed to, either low dose (3 µl/ml) 
or high dose (9 µl/ml) of flaxseed oil or high or low dose of sunflower oil in culture 
media starting on day 0.  The negative control represents treatment with only culture 
media, while the positive controls are cells exposed to camptothecin, rapamycin, 
cyclohexamide or 15 mins of exposure to ultraviolet light.  Harvested, fixed with 70% 
EtOH at -20ºC, blocked and stained by incubating with annexin V-FITC.  The % cells 
were determined as those with greater fluorescence than unstained control cells. (A-
positive treated controls camptothecin 6 hrs, cyclohexamide 6 hrs and rapamycin 6 hrs, 
B-untreated negative controls 24 hrs, 48 hrs and 72 hrs, C-low dose flaxseed oil 24 hrs, 
48 hrs and 72 hrs, D-high dose flaxseed oil 24 hrs, 48 hrs and 72 hrs, E-low dose 
sunflower oil 24 hrs, 48 hrs and 72 hrs, F-high dose sunflower oil 24 hrs, 48 hrs and 72 
hrs) 
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3.4 Cell Cycle and Inhibition of Cell Proliferation  
Cell cycle changes following flaxseed oil treatment was investigated by 
propidium iodide detection by flow cytometry.  Changes in phases of cell cycle in cell 
populations can be determined by the quantity of genetic material.  Following 24 hrs, 
plated cells were treated with either low dose or high dose flaxseed oil and compared to 
the negative untreated controls, and the positive camptothecin treated controls (Figure 
11).  The untreated controls had the majority of their cell population (56%) detected in 
the in the G1 phase and approximately 5% and 22% of cells in sub-G1 at day 1 and day 3, 
respectively (Figure 11- A and E).   The positive control camptothecin had increased cell 
populations in the sub-G1 phase.  Cells treated with camptothecin had 14% of its 
populations in sub-G1 phase on day 1 and over 60% of its cell populations in sub-G1 on 
day 3 (Figure 11- B and F).  Low dose flaxseed oil treated cells had 58% and 44% of 
cells in G1, and 7% and 36% of cells in sub-G1 on days 1 and 3, respectively (Figure 11-
C and G).  High dose flaxseed oil treatment had 48% of its cells in G1 phase for both 
days 1 and 3.  Approximately 15% and 33% of cells were detected in sub-G1 for day 1 
and day 3, respectively (Figure 11- D and H).   These results suggest that both low dose 
and high dose flaxseed oil are effective in significantly increasing cell death in B16-BL6 
cells by day 3 (Figure 11- G and H). 
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Figure 11 Cell cycle analysis of B16-BL6 cells treated with flaxseed oil. 
 
Cell cycle analysis of B16-BL6 cells was determined using propidium iodide stain and 
flow cytometry.  Cells were treated with high dose (9 µl/ml), low dose (3 µl/ml), or 
culture media on day 0 and maintained for the duration of the experiment.  Camptothecin 
was used as a positive control. (A-untreated negative control day 1, B-positive 
camptothecin control day 1, C-low dose flaxseed oil day 1, D-high dose flaxseed oil day 
1, E-untreated negative control day 3, F-positive camptothecin control day 3, G-low dose 
flaxseed oil day 3 and H-high dose flaxseed oil day 3).  All experiments were run in 
triplicate and data were analyzed for 3 experiments. 
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3.5 Lysosome formation in flaxseed oil treated B16-BL6 cells  
Lysosome formation in B16-BL6 cells following flaxseed oil treatment was 
investigated using Lysotracker, a fluorescent probe capable of labeling acidic organelles.  
It was unclear whether the uptake and metabolism of the added fatty acids involved 
phagocytosis and lysosomal degradation.  Cells plated on coverslips were treated with 
either low dose or high dose of flaxseed oil, sunflower oil, or untreated media culture 
(Figure 12).  The positive control cyclohexamide showed significant increases in 
lysotracker stain.  All other conditions, including untreated controls, flaxseed oil and 
sunflower oil treated conditions showed no significant changes in lysotracker stain 
(Figure 12).   This result suggests that neither flaxseed oil nor sunflower oil is capable of 
influencing lysosome presence in B16-BL6 cells.   
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Figure 12 Lysosome formation analysis in flaxseed oil treated B16-BL6 cells by 
lysotracker stain 
 
The formation of lysosomes following flaxseed oil treatment was determined in B16-BL6 
cells.   Cells were treated with high dose (9 µl/ml), low dose (3 µl/ml), of either flaxseed 
oil or sunflower oil and compared to untreated negative controls.  Cyclohexamide was 
used as a positive control.   
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3.6 Mitochondrial Changes in Flaxseed Oil Treated B16-BL6 cells 
 
Mitotracker red is a fluorescent red dye used to stain mitochondria in cells.  Since 
the accumulation of mitotracker red within the cell is dependent on membrane potential, 
this stain is often used in determining apoptosis following treatments.   Cells were plated 
on coverslips and incubated overnight at 37°C.  Cells were treated with low or high dose 
of flaxseed oil or sunflower oil. Rapamycin treatment at 6 mM was used as a positive 
control, while untreated cells were used as negative controls.  Cells were left in treatment 
for 24 hr and 48 hr time periods.  At collection, live cells were washed with PBS, stained 
with mitotracker and then fixed using paraformaldehyde.  Once coverslips were mounted 
on slides, cells were observed using a confocal microscope.  The untreated negative 
controls as well as the sunflower oil treated cells showed large amounts of mitotracker 
red staining within the cells (Figure 13-G and H).  Furthermore, the stain was perinuclear 
and granulated.  This type of staining is indicative of many healthy viable mitochondria 
within the cells (Figure 13-G and H).  The sunflower oil treated cells at both low dose 
and high dose, as well as at both 24 hr and 48 hr time points resembled the healthy viable 
cells detected in the untreated negative controls (Figure 13-I and J).  The sunflower oil 
treated cells had large amounts of staining that was primarily perinuclear and granulated 
(Figure 13-I and J).  The positive control rapamycin treated cells had less staining at 24 
hrs and minimal staining at 48 hrs (Figure 13-A and B).  These findings suggest 
compromised mitochondria and apoptotic cells.  The flaxseed oil treated cells showed 
small amounts of detectable mitotracker stain in their cells (Figure 13-C, D, E and F).  
Perinuclear staining was detectable in the low flaxseed oil treatment at 24 hrs (Figure 13-
C).  This perinuclear staining could not be detected in cells treated with low flaxseed oil 
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for 48 hrs, and for both high flaxseed oil treatments at 24 hrs and 48 hrs (Figure 13-D, E 
and F).  These treated cells had minimal background mitotracker red detection and very 
bright saturated points of staining within the cells.  These findings suggest that 
mitochondrial activity is greatly affected by flaxseed oil treatments at low doses and at 
timepoints as early as 24 hrs (Figure 13-D, E and F).  Furthermore, the loss of viable 
mitochondrial is a characteristic associated with apoptosis. 
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Figure 13 Mitochondrial analysis of flaxseed oil treated B16-BL6 cells using 
mitotracker red 
 
The effect of flaxseed oil treatment on the viability of mitochondria was determined in 
B16-BL6 cells.   Cells were treated with high dose (9 µl/ml), low dose (3 µl/ml), of either 
flaxseed oil or sunflower oil and compared to untreated negative controls.  Rapamycin 
was used as a positive control.  (A-positive rapamycin control 24 hrs, B-positive 
rapamycin control 48 hrs, C-low dose flaxseed oil 24 hrs, D-low dose flaxseed oil 48 hrs, 
E-high dose flaxseed oil 24 hrs, F-high dose flaxseed oil 48 hrs, G-untreated negative 
controls 24 hrs, H-untreated negative controls 48 hrs, I-low dose sunflower oil 24 hrs, J-
low dose sunflower oil 48 hrs, K-high dose sunflower oil 24 hrs and L-high dose 
sunflower oil 48 hrs. 
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3.7 Solvent Extraction of Anti-cancer Components of Flaxseed Oil 
 
A series of experiments were designed to study the chemical properties of the 
biologically active components of flaxseed oil.  Since flaxseed oil is not soluble in media, 
these studies investigated the potential of culture media to act as an extraction solvent.  
Equal parts of flaxseed oil and culture media were mixed together and incubated for 24 
hrs.  Following incubation, a bottom aqueous and a top oil layer formed.  These layers 
were used individually to treat B16-BL6 cells in the same manner as in all previous 
experiments.  These studies showed that cells treated with the top oil layer had a 
significant decrease in cell growth, comparable to samples that were treated with flaxseed 
oil ( p < 0.01) (Figure 14A).  Cells treated with the aqueous layer showed no changes in 
cell growth (Figure 14B).  Therefore the active components remain in the oil layer and 
are not extractable into the aqueous phase.  DMSO, hexane, dichloromethane and 70% 
ethanol were used to further examine the chemical properties of flaxseed oil.  Flaxseed 
oil was combined with each of these agents and their ability to extract chemical 
components into the aqueous phase were determined in subsequent cell growth 
experiments (Figure 15).  None of the four solvents mentioned showed any additional 
inhibition of cell growth on B16-BL6 cells when compared to flaxseed oil only 
treatments.  Furthermore, hexane alone was toxic to the cells and dichloromethane 
prevents the inhibitory effect on cell growth of treating B16-BL6 cells with flaxseed oil 
(Figure 15).  
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Figure 14 Media extraction of the anti-cancer components of flaxseed oil 
The solubility of the active agents in flaxseed oil was determined by extracting the oil 
with tissue culture media and then testing the efficacy of each fraction on B16-BL6 cell 
growth.  Flaxseed oil was combined with media at a 1 to 1 ratio, vortexed and allowed to 
separate over 24 hrs.  Following the 24 hr incubation period, two defined layers formed: a 
top oil layer and a bottom aqueous layer. (* = p < 0.05, ** = p < 0.01) (A-comparison of 
high dose and low dose treatments with top oil layers, B-comparison of high dose and 
low dose treatments with bottom aqueous layers, C-comparison of high dose and low 
dose treatments of flaxseed oil, and D-Comparison of high dose concentrations of oil 
layer, aqueous layer and flaxseed oil treatment) 
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Figure 15 Solvent extraction of anti-cancer components of flaxseed oil 
The solubility of the active agents in flaxseed oil was determined by extracting the oil 
with either, Dichloromethane, DMSO, hexane or 70% ethanol and then testing the 
efficacy of each fraction on B16-BL6 cell growth.  B16-BL6 cells were treated with low 
dose flaxseed oil, high dose flaxseed oil, or a combination of flaxseed oil and one solvent.  
Treatment with pure solvent was used as a control.  Flaxseed treatment was significantly 
different from untreated controls.  There was no significant difference in flaxseed oil 
treatment alone and flaxseed oil plus solvent treatment for any of the four solvents used.   
Hexane alone and in combination with flaxseed oil was toxic to the cells.  (* = p < 0.05,  
**=p <0.01)  A-low dose treatments and 70% Ethanol, B-high dose treatments and 70% 
Ethanol, C-low dose treatments and DMSO, D-high dose treatments and DMSO, E-low 
dose treatments and hexane, F-high dose treatments and hexane, G-low dose treatments 
and dichloromethane, H-high dose treatments and dichloromethane)   
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3.8 Flaxseed Oil Metabolism in B16-BL6 Cells 
 
An experiment was designed to test the hypothesis that B16-BL6 cells are capable 
of metabolizing the omega fatty acids found in flaxseed oil and make the flaxseed oil less 
effective in causing B16-BL6 cell death.  Cells were treated as usual with high dose 
flaxseed oil (9 µl/ml) in large tissue culture plates and incubated for several days (Figure 
16).  Tissue culture plates containing flaxseed oil in media only, and hence no B16-BL6 
cells, were labelled “No Cells” for this experiment.  Tissue culture plates containing 
media but no B16-BL6 cells were also placed in incubators and used as controls and were 
labelled “Control” for this experiment.  At timed intervals, the media from each condition 
was collected and used to treat a set of 5 B16-BL6 96 well plates.  These 96-well plates 
were then used for a new 5 day experiment.  Over time, 96-well plates cells that were 
treated with flaxseed oil media that had been previously exposed to cells, had 
significantly less inhibition in cell growth at 120 hrs than cells that were treated with 
flaxseed oil containing media that was in empty tissue culture plates and left in the 
incubator (p< 0.05) (Figure 16E).  This finding supports the idea that B16-BL6 cells are 
able to metabolize flaxseed oil and utilize as well as deplete the active anti-cancer 
components.  To further investigate this finding, GC/MS was performed on B16-BL6 cell 
membranes to determine fatty acid composition following flaxseed oil treatment (Figure 
17).  The results showed that B16-BL6 cells treated with flaxseed oil had significant 
increases in polyunsaturated fatty acids (PUFA) and decreased amounts in 
monounsaturated fatty acids (MUFA) in the 48 hr samples when compared to untreated 
controls (p < 0.05)  (Figure 17A).  Cells treated with sunflower oil showed comparable 
levels of both PUFA and MUFA to the untreated controls at 48hrs (Figure 17A).  This  
64 
 
 
Figure 16 Omega fatty acid metabolism of flaxseed oil by B16-BL6 cells 
Media containing flaxseed oil was placed in empty tissue culture plates or in tissue 
culture plates plated with B16-BL6 cells and incubated at 37ºC.  Supernatant from these 
plates were collected and used for the treatment of five 96-well plates containing B16-
BL6 cells.  MTT survival assays were performed on these 96-well plates over 5 days.  At 
the 120 hr timepoint, growth of B16-BL6 cells were significantly different between cells 
treated with flaxseed oil incubated on B16-BL6 cells and the flaxseed oil that was 
incubated on an empty plate.  (* = p < 0.05, ** = p < 0.01) 
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Figure 17 GC/MS determination of omega fatty acid composition of cell membranes 
of B16-BL6  
 
Cell membranes of B16-BL6 treated with flaxseed oil or sunflower oil were collected and 
sent for GC/MS analysis at the CCARM laboratory in Winnipeg, Manitoba.  Analysis 
determined levels of saturated fatty acids (SAF), monounsaturated fatty acids (MUFA) 
and polyunsaturated fatty acids (PUFA) (A), as well as levels of specific omega-3 (B) 
and omega-6 fatty acids (C).  (* = p < 0.05, ** = p < 0.01) 
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experiment also looked at levels of specific omega-3 and omega-6 fatty acids present in 
all of the cell membranes of B16-BL6 cells (Figure17B and C).  Cells that were treated 
with flaxseed oil had significantly higher levels of omega-3 fatty acid alpha linolenic acid 
and docosapentaenoic acid when compared to the untreated controls and sunflower 
treated cells at 24 hrs (p< 0.01) (Figure 17B).  Sunflower oil treated cells at 48 hrs had 
significantly higher levels of linoleic acid present in the cell membranes when compared 
to untreated controls (p< 0.05), but had similar amounts of all other omega fatty acids as 
compared to the untreated 48 hr controls (Figure 17C).    
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3.9 Flaxseed Oil Enhances Taxol-Mediated Cell Death in B16-BL6 Cells 
B16-BL6 cells were treated with flaxseed oil in combination with the 
chemotherapeutic agent taxol (Paclitaxel®).  Cells were plated in mini plates and 
incubated overnight at 37ºC to allow adherence.  Following incubation, B16-BL6 cells 
were treated with flaxseed oil, taxol or a combination of flaxseed oil and taxol (Figure 
18).  The taxol concentrations included a high dose of the standard pharmacological 
concentration of 10-5M and decreased by 1000x folds to the lowest concentration of 10-
9M.  After 24 hrs, cells were photographed to determine changes in cell morphology.  
Cells treated with just flaxseed oil or taxol showed rounder cells and apoptotic bodies, 
indicative of cell death.  These morphological changes are more apparent at high dose 
concentrations of either flaxseed or taxol.  B16-BL6 cells treated in combination with 
flaxseed oil and taxol had the largest morphological changes (Figure 18).  Cells that were 
treated with high dose flaxseed oil and low dose 10-9M taxol appeared to have increased 
apoptotic bodies present than those cells treated with 10-9M taxol alone (Figure 18).  
Flaxseed oil treatment in combination with low dose 10-8M taxol was further investigated 
by MTT analysis (Figure 19).  Cells treated with a combination of low dose flaxseed oil 
and low dose taxol had significantly more cell death than cells treated with only low dose 
flaxseed oil or low dose taxol (p< 0.01) (Figure 19A).  These findings suggest that 
supplementing lower concentrations of taxol with low dose flaxseed oil can achieve 
similar effects on cell death than the high concentrations of taxol alone.  Furthermore, the 
supplementation of the natural product flaxseed oil may be capable of reducing the harsh 
side effects caused by the administration of high concentrations of taxol, while still 
obtaining the same anti-cancer effectiveness just at lower doses.                        
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Figure 18 Flaxseed oil enhances taxol-mediated cell death 
Cells were plated in mini plates and treated with increasing concentrations of either 
flaxseed oil, taxol, or a combination of both.  Taxol concentrations consisted of 10-9M, 
10-8M, 10-7M, and 10-6M.  Flaxseed oil concentrations consisted of the standard low dose 
flaxseed oil (3 µl/ml of media) and high dose flaxseed oil (9 µl/ml of media).  Cells were 
photographed using the Fluorchem 100 microscope.   
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Figure 19 Flaxseed oil enhances low dose taxol-mediated cell death 
Cells were plated in 96-well plates and treated with low doses of 10-8M concentrations of 
Paclitaxel in the presence and absence of flaxseed oil.  Each day of treatment, for 5 days, 
the number of cells in each well of the plate was determined using the MTT assay.  
 (** = p < 0.01)   
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4.0 Discussion 
 
4.1 Flaxseed oil and Effects on B16-BL6 Cells 
 
The results of these experiments support the idea that flaxseed oil affects cell 
growth of the aggressive murine melanoma cell line, B16-BL6.  Many of the individual 
components of flaxseed oil have been previously investigated in in vitro experiments22,23, 
however, our studies are the first to look at the effects of flaxseed oil as a whole, and to 
further investigate the metabolism of flaxseed oil following its exposure to cells in an in 
vitro model.  Dr. Thompson and her laboratory at the University of Toronto are at the 
forefront of flaxseed research using in vivo models.  Dr. Thompson has previously shown 
that nude athymic mice fed a diet supplemented with either 5% or 10% flaxseeds showed 
inhibition of the initiation stages of carcinogenesis25.    Dr. Thompson’s laboratory 
focuses on lignans (such as SDG), which are the second largest component of flax seeds 
following the omega fatty acids.  Studies involving lignans are focused around their 
phytoestrogenic properties and their potential to influence estrogen sensitive cancers, 
including breast cancers.  Since phytoestrogens bind to estrogen receptor sites, 
phytoestrogens have the ability to block the interaction between estrogen molecules and 
receptors25.  This blockage enables phytoestrogens to protect woman from estrogen 
promoted cancers25. Lignans however are not found in significant amounts in flaxseed 
oil.  Therefore studies which focus solely on lignans may not be describing the true 
properties of flaxseed oil.  This idea is further supported by our previous studies that have 
looked at the effects of a fabricated “flaxseed oil”.  Omega fatty acids and lignans were 
combined to a 1 to 1 ratio (ALA, LA, GLA, EPA, DHA, ED and ET)38.  Components 
were then dropped out or added into the mixture, and cells counts were determined using 
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the Trypan Blue Survival Assay38.  Although this study has shown that certain 
components may have larger affects than others, the strongest inhibition of cellular 
proliferation occurred when B16-BL6 cells were treated with the complete fabricated 
“flaxseed oil” mixture of the seven compounds each at a concentration of 10-5M 38.  
The current project investigates the effects of various plant oils including 
flaxseed, peanut, canola, sunflower, olive, sesame and grapeseed on cell growth of B16-
BL6 cells.  Each of these oils is composed of various amounts of omega-3, -6 and -9 fatty 
acids.  Each of the seven oils was analyzed by GC/MS and a fatty acid profile was 
determined.  All seven oils were then used to treat the aggressive murine melanoma cell 
line B16-BL6.  Although omega-fatty acids were strongly present in each profile, only 
flaxseed oil was capable of blocking cell proliferation and inducing cellular apoptosis in 
B16-BL6 cells.  These findings further suggest that there is an optimal mixture of omega 
fatty acids that is required to induce apoptosis to the extent that has been shown in this 
study.  This conclusion is also supported by past studies that have focused on the anti-
cancer activities of individual omega-3 fatty acids.  Researchers have shown that in 
animal models that were fed diets supplemented with high amounts of the omega-3 fatty 
acid alpha-linolenic acid, the animals exhibited reduced growth of spontaneous and 
carcinogen-induced mammary tumours57-59.  Furthermore, there have also been various 
studies that investigated the individual effects of treating cancer cells with 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).  One study examined the 
effects of dietary EPA and DHA and their ability to suppress tumour growth in the 
human cancer cell line MDA-MB-43544. Female athymic nude mice were fed diets that 
were supplemented with 4% or 8% of EPA, DHA or ALA, and compared to mice fed the 
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standard non-supplemented feed.  Rose and colleagues found that both the 8% EPA and 
8% DHA fed mice had the smallest growth of tumour implanted in the mammary fat 
pads44.  These experiments show that the individual omega-3 fatty acid components 
found in flaxseed oil may possess some anti-cancer activity.  It is our belief that the 
individual components of flaxseed oil may have a potential additive and/or synergistic 
effect when malignant cell lines are treated with flaxseed oil as a whole rather than as 
fractionated individual components.  This effect may be the result of cellular apoptotic 
induction through various biological pathways. 
 
4.2 Apoptosis and Cell Morphology 
Cell morphology can often be the first telling sign that a cell is undergoing 
apoptosis, a type of cell suicide.  Cell death can be classified as apoptosis, necrosis or 
autophagy60.  Apoptosis is recognized by many morphological changes of which the most 
significant include plasma membrane blebbing, chromatin condensation and nuclear 
fragmentation60.  The current study looked at morphological changes in B16-BL6 cells 
using the acridine orange and ethidium stain and fluorescence microscopy.  Acridine 
orange and ethidium bromide are selective cationic dyes that interact with DNA through 
intercalation.  Acridine orange is cell membrane permeable and stains all cells, while 
ethidium bromide only stains cells when the plasma membrane has been compromised 
such as in necrotic or late apoptotic cells.  Acridine orange fluoresces green while 
ethidium bromide fluoresces red.  This study showed increased morphological changes in 
B16-BL6 cells following treatment with the positive control cyclohexamide and the 
flaxseed oil-treated cells at both high and low doses and time points greater than 24 hr 
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when compared to untreated controls.  Flaxseed oil-treated B16-BL6 cells had increased 
acridine orange and ethidium bromide staining, as well as membrane blebbing as 
compared to control.  The flaxseed oil-treated B16-BL6 cells did not however have 
significant saturation points of ethidium bromide staining until longer time points 
following treatment.  These results indicate that the cells are not necrotic, but instead are 
undergoing apoptosis.  The current study is supported by previously published findings.  
Song et al. 61 detected morphological changes in both pancreatic cell lines, SW1990 and 
PANC-1, following treatment with docosahexaenoic acid.  Furthermore, treatment with 
the omega-6 fatty acid arachidonic acid did not alter the morphology of the pancreatic 
cells61.   Flaxseed oil induced apoptosis in B16-BL6 cells which is an important finding.  
It supports the hypothesis that the cells are receiving a signal from the flaxseed oil and 
biochemically inducing cell destruction rather than swelling up and consequently bursting 
as would be seen in necrotic cells.   
 
4.3 TUNEL and DNA Damage 
DNA is severely damaged during the process of apoptosis.  Although there are 
numerous morphological characteristics of apoptotic cells, DNA fragmentation is not 
limited to histologically defined apoptotic cells, but can also be present in cells 
considered to be morphologically intact62.  It is therefore also important to investigate 
apoptosis using techniques other than cellular morphology stains.  TUNEL stain detects 
DNA damage in situ by labelling dUTP-biotin nicked ends using the enzyme terminal 
deoxynucleotidyl transferase62.  The current study shows increased TUNEL staining in 
the positive control, camptothecin-treated cells, as well as in the flaxseed oil treated cells.  
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Treatment with flaxseed oil at both low and high doses, and at both the 24 hr and 48 hr 
treatment time points, increased the number of TUNEL stained cells compared to 
untreated and sunflower-treated cells.  The cells treated with high dose of flaxseed oil for 
48 hrs had very bright staining.  This is an indication of increased DNA breaks often 
associated with late phase apoptosis.  These findings are similar to other published results 
that have looked at the ability of treatment with individual omega-3 fatty acids to induce 
apoptosis.  Song et al.61 found docosahexaenoic acid treated SW1990 pancreatic cancer 
cells after 24 hrs had an increased number of TUNEL-positive cells when compared to 
the untreated controls and to the omega-6 fatty acid treated cells.  Morin et al.63 also 
found similar results when studying the effect of docosapentaenoic acid, an omega-3 fatty 
acid that has received very little attention on cell death.  Morin’s research group showed 
that in HCT116 tumour-bearing nude mice, orally administered docosapentaenoic acid 
monoglyceride, showed an increase in apoptotic cancer cells63.  The apoptotic index was 
calculated at 48 ± 2.5% in tumour sections derived from docosapentaenoic acid 
monoglyceride treated mice and 4.5 ± 0.9% in tumour sections from control mice63.  The 
ability of cancer cells to escape apoptosis is a hallmark characteristic of cancer under 
normal conditions.  Therefore any natural products that have the ability to activate 
apoptotic pathways in cancer cells are of high importance in developing anti-cancer 
therapeutics.   
 
4.4 Annexin V-FITC and Apoptosis 
The current studies have determined that flaxseed oil induced cell death in B16-
BL6 cells through the activation of the apoptotic pathway.  There are two pathways that 
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are involved in the apoptotic process, the intrinsic and the extrinsic pathway.  The current 
study has examined apoptosis in B16-BL6 cells following flaxseed oil treatments using 
DNA fragmentation gels, fluorescence microscopy and flow cytometry.  Previous work 
on this project showed that flaxseed oil activated apoptosis through the extrinsic pathway.  
Western blot analysis showed caspase cleavage following 24 hr treatment with flaxseed 
oil38.  Our previous studies also showed increased DNA fragmentation in flaxseed oil-
treated cells compared to untreated controls (Appendix C)38.  The current studies have 
further investigated the induction of apoptosis following flaxseed oil treatment.  Flow 
cytometry was used to look at changes in Annexin V staining in B16-BL6 cells at 24 hrs, 
48 hrs and 72 hrs, following flaxseed oil treatment.  Under normal physiological 
conditions, phosphatidylserines are located on the cytosolic side of the plasma 
membrane.  Following physiological triggers and the induction of apoptosis, 
phosphatidylserines are translocated to the outer edge of the cell membrane64,65.  This 
shift in phosphatidylserines from the inner membrane to the outer membrane signals to 
surrounding phagocytic cells to target the cell for phagocytosis and destruction.  This 
translocation step also allows for Annexin V labelling, and cells currently undergoing 
apoptosis can be detected by FACS analysis using the Annexin V-FITC conjugate.  The 
current study shows increased detection of Annexin V-FITC binding to cyclohexamide-
treated cells, the positive control, and to the flaxseed oil-treated cells at both doses (low 
and high) as well as at all time-points (days 1, 2 & 3) when compared to untreated 
controls and sunflower oil-treated cells.  These findings are consistent with previously 
published works.  Researchers have previously shown that omega-3 fatty acid-rich oils, 
such as flaxseed oil, are able to provide protection against the progression of colon 
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cancers, whereas omega-6 fatty acid-rich oils such as sunflower oil, may in contrast 
promote tumourigenesis in these same colon cancers65.  Bommareddy et al. 65 showed by 
FACS analysis using Annexin V staining, that alpha-linolenic acid at concentrations of 
800 µM and 1000 µM significantly induced apoptosis in the human colon 
adenocarcinoma cells, Caco-2.  Bommareddy et al. 65 further showed that lower 
concentrations (500 µM) of alpha-linolenic acid could also induce similar levels of 
apoptosis in Caco-2 cells, if administered in combination with 75 µM of either 
enterolactone or enterodiol, two lignans found within flaxseed oil.  It is suggested that the 
higher concentrations of alpha linolenic acid that were required to induce apoptosis to the 
same degree as was accomplished by sole treatment with enterodiol or enterolactone, 
may in part be due to alpha-linolenic acid being metabolized into its longer chain 
counterparts, eicosapentaenoic acid and docosahexaenoic acid65.  As previously 
mentioned, this conversion is an inefficient process and therefore larger amounts of 
alpha-linolenic acid are required to produce sufficient amounts of the active metabolites.   
 
4.5 PI Stain and the Cell Cycle 
FACS analysis was further used to determine the effects of flaxseed oil on cell 
division and the cell cycle in B16-BL6 cells.  Propidium iodide, a stoichiometric stain, 
was used to determine DNA content and hence enable B16-BL6 cells to be classified into 
phases of the cell cycle based on DNA content.  This study showed that B16-BL6 cells 
stained with propidium iodide had significant changes in cell populations for the various 
phases of the cell cycle in both the positive control-treated cells, which included 
camptothecin-treated cells, as well as the flaxseed oil-treated cells when compared to the 
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untreated cells.  FACS analysis of B16-BL6 cells at 24 hrs and 36 hrs following flaxseed 
treatments, showed increased cells numbers in sub G1 phase of the positive control, 
camptothecin-treated  cells, as well as cells treated with both doses of flaxseed oil when 
compared to untreated control cells.  These findings are supported by previously 
published work. Song et al.61 have shown the effect of docosahexaenoic acid on the 
pancreatic cell line SW1990.  Their studies showed that docosahexaenoic acid resulted in 
an increased sub-G1 population for SW1990 cells.  Furthermore, the effect of 
docosahexaenoic acid treatment was shown to be dose-dependent61.  Although these 
findings support our current studies, there are still important differences to point out.  For 
example, the majority of research currently takes place using complex mixtures of 
omega-3 fatty acids, while this study focuses on one individual member of the omega-3 
fatty acid family, docosahexaenoic acid, and its effect on the cell cycle. Our studies are 
complicated by using flaxseed oil as a whole.   Dekoj et al.66 is one of few laboratories to 
investigate the effects of omega-3 fatty acids in combination and their effects on cancer 
cell growth.    The Dekoj research group uses omega-3 fatty acid and omega-6 fatty acid 
emulsions purchased from Fresenius-Kabi in Bad-Homburg, Germany66.  The omega-3 
fatty acid emulsion, Omegaven®, and the omega-6 fatty acid emulsion, Lipovenoes®, are 
clinically used for parenteral nutrition66.  MIA PaCa-2, human pancreatic ductal 
adenocarcinoma cells, showed cell cycle arrest at the G2/M interface when treated with 
the omega-3 fatty acid emulsion for 24 hrs66.  Similar to our findings, Dekoj et al. 66 
showed increased sub-G1 populations in MIA PaCa-2 cells at 48 hrs post omega-3 fatty 
acid emulsion treatments.  Further supporting our findings, cells treated with omega-6 
fatty acid emulsion showed no differences at both 24 hr and 48 hr time points when 
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compared to the untreated controls.  This study also showed a dose-dependent response66.  
Since most people have a tendency to take omega-3 supplements which contain more 
than one omega-3 fatty acid, it is beneficial to look at the additive and synergistic effect 
that multiple omega-3 fatty acids may have on cellular process.  Since flaxseed is an 
excellent source of omega-3 fatty acids, these studies may provide insight into these 
complex relationships.  
 
4.6 Mitochondrial and Lysosomal Changes in Flaxseed Oil Treated Cells 
It has been shown that apoptosis can be induced in cells via two pathways47-49.  
The external pathway requires a ligand to bind to a death receptor on the cell membrane, 
while the internal pathway induces apoptosis following destabilization of the 
mitochondrial membrane potential47-49.  Our previous results have shown that flaxseed oil 
is capable of inducing apoptosis through the external pathway38.  The current study 
confirmed by mitotracker red stain that cells treated with flaxseed oil can also induce 
apoptosis through mitochondrial destabilization and hence the internal apoptotic pathway.   
Following treatment with flaxseed oil, cells had significantly less mitotracker red stain 
when compared to the untreated controls.  The mechanism by which omega-fatty acids 
induce apoptosis in cancer cells is poorly understood.  It has been suggested that omega-3 
fatty acids negatively affect mitochondria by increasing the levels of reactive oxygen 
species (ROS) within the cells41.  It has also been suggested that ROS may be capable of 
inducing apoptosis in cells through the permeabilization of lysosomal membranes41.  Our 
studies however did not show any changes in lysosome formation following flaxseed oil 
treatment when compared to the untreated controls.   Therefore, further studies which 
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focus on mitochondrial membrane destabilization following flaxseed oil treatment are 
required. 
 
4.7 Omega-3 Fatty Acid Metabolism 
Omega-3 fatty acids have been showed to have multiple cellular functions.  
Changes in environmental levels of omega-3 fatty acids have the ability to greatly 
influence membrane fluidity and consequently can affect biological processes that take 
place either within, or close to cell membranes67.  These processes can include enzymatic 
functions, receptor-ligand interactions, cell-cell interactions and nutrient transport 
through the membrane67.  There have been two proposed hypotheses on how omega-3 
fatty acids are able to disperse themselves through the cell membrane.  The first suggests 
passive diffusion, where fatty acids use their hydrophobic tail to penetrate the outer 
leaflet of the cell membrane68.  The omega-3 fatty acid is then able to rotate in a slow 
moving manner, dispersing itself within the bilayer, and ultimately finishing up on the 
inner leaflet of the cell membrane68.  This displacement is regulated by both the physical 
properties of the cell membrane, as well as the structural properties of the individual 
omega-3 fatty acid68.  The second mechanism is described as active transport which is 
mediated through plasma membrane fatty acid-binding proteins, fatty acid translocases, 
and fatty acid transport proteins68.  It is also widely accepted that omega-3 fatty acids 
present in the cell membrane are enzymatically metabolized in response to certain 
physiological triggers.  Cyclooxygenases and lipoxygenases metabolize omega fatty acids 
to form prostaglandins and leukotrienes, respectively69.  Although the current study does 
not attempt to identify which of the proposed mechanisms mediates how the flaxseed oil 
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drug treatment is transported into the cell membrane or which enzymes are utilized for its 
metabolism, our results from the metabolism experiment do support the notion that 
flaxseed oil is capable of incorporating itself into the membrane and can then be 
metabolized into its longer chain counterparts in the cell membrane of B16-BL6 cells.  
Fatty acid metabolism has been investigated in hepatocytes by Alhazzaa et al. 69.  This 
group found that alpha-linolenic acid bioconversion to the longer chain polyunsaturated 
fatty acids, eicosapentaenoic acid and docosapentaenoic acid, can be attributed to various 
factors including enzyme affinity, substrate availability as well as transcriptional 
factors69.  Furthermore, direct competition between omega-3 fatty acids can also affect 
bioconversion efficiencies.  It has been suggested that metabolism of alpha-linolenic acid 
competes for enzymes, and therefore limits docosahexaenoic acid metabolism, and 
consequently formation of its longer metabolite docosapentaenoic acid in hepatocyte 
membranes70,71.  Our current study has not further investigated this limitation.  However, 
our studies did show that docosapentaenoic acid was present in B16-BL6 cell membranes 
in significantly higher quantities at 3 days, following flaxseed oil treatments, as compared 
to untreated controls.  Since a significant increase in cell death can be identified at day 3, 
it may be plausible that alpha-linolenic acid metabolism may require 3 days, in order to 
produce sufficient amounts of omega-3 fatty acids metabolites which are capable of 
inducing apoptosis.  Alhazzaa et al.69 showed that eicosapentaenoic acid levels could be 
detected in FaO cells only after 3 days following administration of 50 µM of alpha-
linolenic acid.  It was further concluded that following day 3, significant increases in 
docosapentaenoic acid and docosahexaenoic acid levels could be detected in the cell 
membranes of FaO cells, while there was a notable reduction in eicosapentaenoic acid 
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levels69.  This finding suggests that periods of longer than 3 days are required for alpha-
linolenic to be converted to its long chain metabolite, docosahexaenoic acid.  
   
4.8 Flaxseed Oil and Chemotherapeutic Agents 
Omega-3 fatty acids have been described as extraordinary compounds that have 
the ability to slow cancer cell proliferation and increase chemotherapy effectiveness, all 
while calming the common side effects of chemotherapies and cancer progression72.  It is 
believed that omega-3 fatty acids have the ability to alter toxicities and/or the activity of 
chemotherapies that are administered to cancer patients undergoing treatment.  As 
previously mentioned, omega-3 fatty acids alter membrane fluidity and membrane-
mediated functions.  The current study showed that flaxseed oil treatment of B16-BL6 
cells in combination with paclitaxel-enhanced cell death.  This finding is supported by a 
newly synthesized chemotherapeutic drug.  DHA-paclitaxel has been developed by 
covalently conjugating docosahexaenoic acid to the paclitaxel molecule.  A Phase 3 study 
in patients provided supportive data that this new DHA-paclitaxel drug has increased 
anti-cancer activity and improved therapeutic applications73.  The efficiency of using 
omega-3 polyunsaturated fatty acids in combination with chemotherapeutic drugs is 
dependent on the omega-3 fatty acid, the chemotherapeutic drug, and the type of cancer 
that is being treated73.  Farhmann et al.74, showed that eicosapentaenoic acid and 
docosahexaenoic acid were effective at increasing doxorubicin cytotoxicity in B-
leukemic cells.  In MDA-MB-231 breast cancer cells, docosahexaenoic acid decreased 
cell viability to 21% when administered with doxorubicin25,26.  Doxorubicin alone 
decreased cell viability to only 54%.  The suggested mechanism by which 
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docosahexaenoic acid increases doxorubicin cytotoxicity has been credited to its effect on 
generating lipoperoxides25,26.  Further research on omega-3 fatty acids and their 
interactions with chemotherapeutic drugs is needed to determine their full potential. 
 
4.9 Future Directions- Cell Signaling 
The effects of flaxseed oil are complicated by the combination of the individual 
effects of each omega-3 fatty acid.  In order to rationalize the effects of flaxseed oil 
treatment, the activation of signalling pathways as measured by transcription factor 
activation were assayed.  The level of transcription factor activation measured as the level 
of luciferase production from specific promoter elements was determined in flaxseed oil 
treated and untreated transfected cells.  The luciferase signaling assay was not conclusive 
in determining which pathway or pathways are activated and/or inhibited in B16-BL6 
cells following flaxseed oil treatment, and further experiments are necessary to identify 
key signaling pathways.  Previously published work has shown certain pathways to be 
altered in the presence of omega fatty acids.  In hepatocarcinoma cells, eicosapentaenoic 
acid is credited with inhibition of cell proliferation, whereas docosahexaenoic acid is 
credited with the induction of apoptosis75.  The induction of apoptosis following 
treatment of docosahexaenoic acid is suggested to include the ability to modify 
expression levels of the Bcl-2 protein family76.  Docosahexaenoic acid is capable of 
increasing levels of pro-apoptotic proteins Bak and Bcl-xS and additionally decreasing 
levels of anti-apoptotic proteins Bcl-2 and Bcl-xL76.  Researchers have furthermore 
shown that docosahexaenoic acid can also potentially induce cytochrome c release 
consequentially depolarizing mitochondrial membranes77.  These results therefore 
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suggest that docosahexaenoic acid has the ability to activate apoptotic pathways.  
Eicosapentaenoic acid on the other hand has been credited with inhibiting cell 
proliferation.  Sauer et al.78 showed that eicosapentaenoic acid inhibited cell proliferation 
in MCF-7 human breast cancer cells by binding to a cell surface inhibitory GPC FFAR 
protein.  This binding causes an inhibition of adenylyl cyclase and subsequently a 
reduction of intra-tumour cAMP78.  However, like the additive benefit of treating patients 
with both chemotherapies and omega-3 fatty acids, noticeable changes in signalling 
pathways are dependent on the cancer cell type, as well as omega-3 fatty acid dosages.  
Researchers have previously found varying results in cell signalling pathways due to 
these variables.  In vascular smooth-muscles Tachjian et al.79, showed that 
docosahexaenoic acid actually had a greater effect on cell proliferation than 
eicosapentaenoic acid.  These differences make it important to consider each cell line 
individually and to test varying concentrations of omega-fatty acids, as these two factors 
may influence metabolism and incorporation in mammalian cells75.  Our studies may also 
show insight on how the administration of combinations of omega-3 fatty acids may also 
be capable of varying the outcome on cell growth and cell death. 
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5.0 Conclusion 
Although the underlying mechanisms have yet to be determined, published works 
show that omega-3 fatty acids are capable of prolonging survival of cancer patients by 
reducing the effects of cancer, and by providing relief of symptoms often associated with 
malignancy.  Since the Western diet has a grossly imbalanced omega-3 to omega-6 fatty 
acid ratio, it is important to incorporate foods that are high in omega-3 fatty acids into our 
daily diets.  Flaxseed oil is one of the highest plant sources of the omega-3 fatty acid 
alpha-linolenic acid.  These studies have shown that B16-BL6 cells are capable of 
incorporating and metabolizing alpha-linolenic acid into longer chain omega-3 fatty acids 
in the cell membrane.  Previously published work has shown the cellular changes omega-
3 fatty acids can have when incorporated into the diet and/or used for treatment. Our 
studies heavily support these changes, including inhibition of cellular proliferation and 
induction of cellular apoptosis in malignant cells.  Although these studies were 
unsuccessful in determining the exact mechanism by which flaxseed oil is capable of 
interacting with B16-BL6 cell membranes, we have concluded that flaxseed oil can be 
metabolized within the cell membrane into the longer chained omega-3 fatty acids 
(Figure 20).  These studies have shown that following metabolism is the cell membrane, 
the longer chained omega-3 fatty acids induced apoptosis by cleaving caspase-3 while 
simultaneously destabilizing mitochondrial potential resulting in apoptosis (Figure 20).  
Furthermore, our studies have shown the potential for optimizing chemotherapeutic 
treatments using Paclitaxel® and flaxseed oil in combination.  These findings should be 
of clinical importance and the results of these studies may provide a basis for the 
development of a powerful anti-cancer drug with minimal side effects.  Future works 
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include further investigation of the metabolism of fatty acids within the cell membranes.  
Once the metabolism of omega-3 fatty acids within malignant cell membranes is 
understood, experiments focused on the interaction of specific omega-3 fatty acids with 
one another as well as with intracellular signalling proteins will allow for the 
development of a flaxseed oil based drug that can be tested in vivo.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20 Proposed hypothesis of how flaxseed oil is metabolized within the cellular 
membrane resulting in the activation of the apoptotic pathway. 
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Appendix A Effect of flaxseed oil on the growth of the malignant B16-BL6 cell line 
and the non-malignant cell line HSG. 
 
The change in cell number for B16-BL6 melanoma cells and HSG (human salivary 
gland) cells exposed to various concentrations of flaxseed oil treatments (1, 3, 6, 9 and 12 
µl of flaxseed oil per millilitre of media) were determined by counting live cells after 
trypan-blue staining using a hemacytometer.  Cells were subcultured at approximately 
30% confluency one day prior to the experiment.  The cells were treated with the 
indicated dose of flaxseed oil on day 0 and maintained for the duration of the experiment.  
All experiments were run in triplicate and data were analyzed for 3 experiments.  A) The 
effects of flaxseed oil on cell growth of the aggressive murine melanoma cell line B16-
BL6.   B) The effects of flaxseed oil on cell growth of the non-malignant HSG cell line.   
(*= p < 0.05) 
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Appendix B MTT (Thiazol blue tetrazolium bromide) analysis of the cell growth of 
flaxseed treated malignant and non-malignant cell lines. 
 
The viability of cultures of the malignant A) MDA-MB-231, B) MCF-7 and suspension 
C) THP-1 cells and the non-malignant D) HSG, E) HBL100, and F) 293T cells treated 
with flaxseed oil was determined using an MTT assay.  The cells were treated with high 
dose (9 µl/ml), low dose (3 µl/ml), or culture media on day 0 and maintained for the 
duration of the experiment.  (*= p < 0.05) 
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